- Details
- In this discussion between Kara Maxwell and Alicia Morgans, Dr Maxwell highlights the role of TP53 in cancer and understanding the Li-Fraumeni syndrome. Inherited germline TP53 pathogenic and likely pathogenic variants (gTP53) cause autosomal dominant multicancer predisposition including Li-Fraumeni syndrome and the work that Drs. Morgans and Maxwell discuss here sought to determine whether gTP53...
|
- Details
- Alicia Morgans speaks with Kim Chi about the MAGNITUDE trial presented at GU ASCO 2022. The Phase III trial investigates the efficacy of combining niraparib, a PARP inhibitor, with abiraterone and prednisone in treating metastatic castration-resistant prostate cancer (mCRPC). The study focuses on patients with and without homologous recombination repair (HRR) gene alterations. Results reveal that...
|
- Details
- Stuart Bloom, MD, a well-known Twin Cities oncologist, joins Charles Ryan, MD to highlight his work on physician burnout including his theatrical play “How to Avoid Burnout in 73 Minutes”. The play represents Dr. Bloom's path to becoming a physician. Dr. Bloom spent the first 30 years of his life as an actor and comedian, the next 31 as a physician. In this conversation, the pair discuss how he co...
|
- Details
- Diane Newman hosts Leanne Schimke to explore the complexities of metastatic prostate cancer with a focus on the role of genomics and PARP inhibitors. Dr. Schimke delves into how advancements in genomics are providing new avenues for personalized treatment, although the field lags about a decade behind breast cancer research. She highlights the importance of differentiating between indolent and agg...
|
- Details
- In this UroToday discussion Alicia Morgans and Ana Aparicio, discuss androgen indifferent prostate cancer and how to define those patients. The conversation kicks off with a discussion on the challenges of defining androgen indifferent prostate cancer patients. Dr. Aparicio then goes into a discussion on TP53, RB1, and PTEN alterations, and how they fit into her recent studies. Dr. Morgans and Dr....
|
- Details
- Alica Morgans is joined by Ronald Tutrone to provide an update on the clinical trial VERU 100. VERU‑100 is a novel, proprietary long-acting gonadotropin-releasing hormone (GnRH) antagonist peptide 3-month subcutaneous depot formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT). Biographies: Ronald Tutrone, MD, FACS, CPI, National Med...
|
- Details
- In a discussion hosted by Alicia Morgans, Neeraj Agarwal delves into the promising results of the COSMIC-021 study. The study focuses on the combination of cabozantinib and atezolizumab for treating patients with metastatic castrate-resistant prostate cancer (mCRPC). Dr. Agarwal highlights the unique inclusion criteria of the study, which required patients to have progressive measurable disease in...
|
- Details
- Alicia Morgans, MD, MPH, and Michael Cookson, MD, MMHC, FACS, discuss age subgroups in the HERO trial, evaluating differences in castration rates between patients of different ages from the HERO Study. The HERO trial evaluated relugolix compared to standard androgen deprivation therapy with leuprolide. Dr. Cookson discusses how they performed the analysis. The evaluation demonstrated that younger...
|
- Details
- Tom Keane, MBBCh, FRCSI, FACS, recaps the HERO Phase III Trial comparing the safety and efficacy of relugolix with leuprolide acetate in advanced prostate cancer patients. In this trial, men with advanced prostate cancer who received relugolix achieved rapid, sustained suppression of testosterone levels that were superior to that with leuprolide, with a 54% lower risk of major adverse cardiovascul...
|
- Details
- In this UroToday discussion Charles Ryan and Brandon Mahal, discuss Dr Mahal’s recent update to his study that was published in last year’s New England Journal of Medicine. Dr. Mahal begins this conversation by discussing the background of his recent study, discussing the differences in mutational landscape, of advanced prostate cancer patients, between men with European and African ancestry. Dr....
|
